Merck launches Saflutan in first European markets
September 4, 2009Research and Development, Sales and Marketing Merck, ophthalmology
Merck's glaucoma drug Saflutan has been launched in the UK and Spain. The manufacturer says more launches are planned in …
Novartis swine-flu jab effective in single dose
September 3, 2009Manufacturing and Production, Research and Development, Sales and Marketing Novartis, h1n1
A study of Novartis' pandemic swine-flu jab shows it is potentially protective after just one dose, which could help eke …
Pharmafocus expands into Europe
September 3, 2009Research and Development, Sales and Marketing Europe
The September issue of Pharmafocus marks a new stage in the publication’s development with an expanded monthly circulation that takes …
Merck unveils post-merger leadership team
September 3, 2009Research and Development, Sales and Marketing MA, Merck
The make-up of Merck and Schering-Plough's new corporate entity became clearer this week. Referred to as the 'new Merck' and …
Pfizer shamed with $2.3bn fine for marketing fraud
September 3, 2009Sales and Marketing Pfizer, US, illegal, off label prescribing
The US government has imposed a $2.3 billion fine on Pfizer for a string of offences including illegal off-label prescribing …
New cancer cases set to hit 17 million by 2020
September 2, 2009Research and Development, Sales and Marketing Cancer, healthcare
The next ten years will see a 30% leap in the number of new cancer cases across the world, according …
Pandemic planning: GSK’s Dr Neil Formica
September 1, 2009Research and Development GlaxoSmithKline, Vaccine, h1n1
UCB and Novartis expand alliance in Germany
September 1, 2009Sales and Marketing Germany, Novartis, UCB
UCB and Novartis have extended their partnership in Germany with a new licensing deal for the cardiovascular and diabetes drug …
Shire goes for early approval in Gaucher disease
September 1, 2009Research and Development, Sales and Marketing Gaucher's, Shire
Shire has filed for early US approval of its Gaucher disease drug velaglucerase alfa, as supplies to Genzyme's established rival …
Pradaxa data boosts Boehringer
September 1, 2009Research and Development, Sales and Marketing Boehringer, Pradaxa
Boehringer Ingelheim has unveiled new positive data for its blood-thinner Pradaxa, showing it reduces the risk of stroke compared to …
Pfizer agrees price cut in Clinton deal
September 1, 2009Research and Development, Sales and Marketing HIV, Pfizer, price cuts
Former US President Bill Clinton has brokered major new deals with Pfizer and Mylan to cut the price of tuberculosis …
Indian government accepts pro-patent report
September 1, 2009Research and Development, Sales and Marketing Asia, India, patents
The government of India has accepted the findings of a report into its patent laws, which recommends maintaining a higher …
EU divided over patient information proposals
September 1, 2009Sales and Marketing EFPIA, Europe, patient information
Europe’s member states are at loggerheads over plans to relax current restrictions on pharma communicating with patients.The plans tabled by …
Basilea buoyed by sales increase
September 1, 2009Research and Development, Sales and Marketing Basilea
Swiss pharma company Basilea Pharmaceutica has unveiled encouraging interim financial results, showing it has doubled its sales and decreased its …
JLL says it will fight Lonza’s Patheon bid
September 1, 2009Manufacturing and Production JLL, Patheon
Lonza's attempt to buy Canadian contract manufacturer Patheon will not go unopposed by private equity group JLL, which has been …
Supply chain controls blamed for UK medicines shortage
August 27, 2009Manufacturing and Production, Research and Development supply chain
Industry supply chain controls in the UK have overwhelmingly made medicines more difficult to source and have put patients risk, …
Americans doubt benefits of health reform
August 27, 2009Research and Development, Sales and Marketing US, US healthcare, healthcare
Most Americans are satisfied with their existing medical arrangements, according to a survey by Thomson Reuters.The results seem to be …
NICE criticised for rejection of kidney cancer drugs
August 27, 2009Research and Development, Sales and Marketing Kidney cancer, NICE, Nexavar
Three treatments for advanced kidney cancer have been rejected by NICE, sparking criticism from pharma companies and patient groups.The drugs …
Venezuela restates threat to seize Pfizer plant
August 27, 2009Manufacturing and Production, Sales and Marketing Pfizer, South America
The wrangling over Pfizer's manufacturing facility in Venezuela is continuing, with a senior official reiterating a threat to seize control …
Novartis unveils new lab approach to boost research capacity
August 27, 2009Research and Development Novartis, Switzerland
Novartis has unveiled a new research approach involving novel lab technology and flexible working, in the hope to speed its …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
